Hillsdale Investment Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Hillsdale Investment Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-337,800	Closed	-$993K	–	579
2018 Q1	$993K	Hold	337,800	–	–	0.14%	152
2017 Q4	$926K	Buy	337,800 +24,293	+8%	+$74.6K	0.15%	164
2017 Q3	$1.06M	Buy	+313,507	New	+$872K	0.18%	132
2016 Q1	–	Sell	-10,000	Closed	-$35K	–	591
2015 Q4	$35K	Sell	10,000 -39,000	-80%	-$163K	0.01%	348
2015 Q3	$246K	Buy	49,000 +2,500	+5%	+$14.3K	0.08%	263
2015 Q2	$299K	Hold	46,500	–	–	0.09%	255
2015 Q1	$327K	Buy	46,500 +20,600	+80%	+$149K	0.08%	265
2014 Q4	$200K	Buy	25,900 +13,000	+101%	+$103K	0.05%	326
2014 Q3	$96K	Buy	+12,900	New	+$120K	0.03%	388

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Hillsdale Investment Management's PDLI Position: Q2 2018 in Review

Hillsdale Investment Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 337,800 shares — an estimated $993K sold.

Hillsdale Investment Management first reported a position in PDLI in Q3 2014 and held it in 9 quarters. The position peaked at $1.06M in Q3 2017. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Hillsdale Investment Management reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Hillsdale Investment Management sold 337,800 PDL BioPharma, Inc. shares in Q2 2018, an estimated $993K.
Hillsdale Investment Management first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 9 quarters.
Hillsdale Investment Management's PDL BioPharma, Inc. position peaked at $1.06M in Q3 2017.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Hillsdale Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.